نتائج البحث - Chandiwana, David

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom حسب Suri, Gaurav, Chandiwana, David, Lee, Adam, Mistry, Rohit

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews حسب Romano, Carla, Harris, Nimanee, Gnanasakthy, Ari, D’Alessio, Denise, Chandiwana, David

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer حسب Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer حسب Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom حسب Amdahl, Jordan, Diaz, Jose, Sharma, Arati, Park, Jinhee, Chandiwana, David, Delea, Thomas E.

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil حسب Buehler, Anna Maria, Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Igho-Osagie, Ebuwa

احصل على النص الكامل

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer? حسب Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Shor, Anastasiya, Tremblay, Gabriel

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... حسب Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer حسب Turner, Stuart, Chia, Stephen, Kanakamedala, Hemanth, Hsu, Wei‐Chun, Park, Jinhee, Chandiwana, David, Ridolfi, Antonia, Yu, Chu‐Ling, Zarate, Juan Pablo, Rugo, Hope S.

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer حسب Fasching, Peter A, Delea, Thomas E, Lu, Yen-Shen, De Boer, Richard, Hurvitz, Sara A, Moynahan, Aaron, Chandiwana, David, Lanoue, Brad, Hu, Huilin, Thuerigen, Astrid, O’Shaughnessy, Joyce

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results f... حسب Harbeck, Nadia, Franke, Fabio, Villanueva-Vazquez, Rafael, Lu, Yen-Shen, Tripathy, Debu, Chow, Louis, Babu, Govind K, Im, Young-Hyuck, Chandiwana, David, Gaur, Anil, Lanoue, Brad, Rodriguez-Lorenc, Karen, Bardia, Aditya

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer حسب Tripathy, Debu, Curteis, Tristan, Hurvitz, Sara, Yardley, Denise, Franke, Fabio, Babu, K. Govind, Wheatley-Price, Paul, Im, Young-Hyuck, Pencheva, Radost, Eddowes, Lucy A., Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Lanoue, Brad, Harbeck, Nadia

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study حسب Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd

احصل على النص الكامل احصل على النص الكامل احصل على النص الكامل